Regeneron Pharmaceuticals Inc at BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology (Virtual) Transcript
Good morning. My name is Bert Powell. I'm the Global Director of Research here at BMO Capital Markets. Thank you for joining us today.
Life science continues to be a core area of focus for us here at BMO and our Biopharma Spotlight Series has been a terrific platform to go deeper into specific therapeutic areas. Past events are focused on protein degradation, other next-gen protein technologies, and tech-enabled drug discovery. Stay tuned. We will be announcing our next Biopharma Spotlight Series in the not-too-distant future.
Today's series will focus on rare disease and ophthalmology. We have a great lineup of fireside chats with Regeneron, Horizon Therapeutics and Ionis, 3 leading companies in these areas. As well, we have 3 KOLs -- 2 KOLs and 3 panels on ophthalmology, rare CNS diseases and rare autoimmune and genetic diseases. Today's spotlight series will be moderated by our senior research analysts, Gary Nachman, and Matt Luchini.
I also wanted to take this opportunity to share with you some very exciting news. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
